[抗代谢药物与烷化剂联合治疗晚期乳腺癌]
[Combination of antimetabolites and alkylating agents in the treatment of advanced breast cancer].
作者信息
Germiniani R, Pipino G, Lavorato F, Bressani Doldi S
出版信息
Minerva Med. 1977 Mar 17;68(13):831-4.
PMID:321989
Abstract
An association of 5-fluoruracyl (or methotrexate) and cyclophosphamide was used in the treatment of 20 cases of hormone-resistant breast cancer. Five objective regressions were obtained. Mean survival here was 28.25 (S.D. 2.87) months, as opposed to 12.75 (S.D. 6.93) months in the remainder. Side-effects of various kinds were noted in 9 patients.
摘要
采用5-氟尿嘧啶（或甲氨蝶呤）与环磷酰胺联合治疗20例激素抵抗性乳腺癌患者。获得了5例客观缓解。此处患者的平均生存期为28.25（标准差2.87）个月，而其余患者为12.75（标准差6.93）个月。9例患者出现了各种副作用。
Zotero 插件